[go: up one dir, main page]

UY26130A1 - Compuestos para tratar la obesidad - Google Patents

Compuestos para tratar la obesidad

Info

Publication number
UY26130A1
UY26130A1 UY26130A UY26130A UY26130A1 UY 26130 A1 UY26130 A1 UY 26130A1 UY 26130 A UY26130 A UY 26130A UY 26130 A UY26130 A UY 26130A UY 26130 A1 UY26130 A1 UY 26130A1
Authority
UY
Uruguay
Prior art keywords
compounds
treat obesity
npy
npy antagonists
antagonists
Prior art date
Application number
UY26130A
Other languages
English (en)
Inventor
Elliot Hammon Hank
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26130A1 publication Critical patent/UY26130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Antagonistas de NPY, procedimientos para usar tales antagonistas de NPY y composiciones farmacéuticas que contienen tales antagonistas de NPY. Los antagonistas de NPY son útiles para el tratamiento de enfermedades/trastornos inducidos por NPY, incluyendo la obesidad.
UY26130A 1999-04-30 2000-04-27 Compuestos para tratar la obesidad UY26130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13202999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
UY26130A1 true UY26130A1 (es) 2000-12-29

Family

ID=22452122

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26130A UY26130A1 (es) 1999-04-30 2000-04-27 Compuestos para tratar la obesidad

Country Status (12)

Country Link
US (2) US6355635B1 (es)
AR (1) AR028824A1 (es)
AU (1) AU2935200A (es)
CO (1) CO5170414A1 (es)
GT (1) GT200000057A (es)
HN (1) HN2000000041A (es)
MA (1) MA26730A1 (es)
PA (1) PA8493701A1 (es)
PE (1) PE20010118A1 (es)
TN (1) TNSN00092A1 (es)
UY (1) UY26130A1 (es)
WO (1) WO2000066578A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044201A1 (en) 1999-12-16 2001-06-21 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
JP2005517654A (ja) * 2001-12-17 2005-06-16 メルク　エンド　カムパニー　インコーポレーテッド 日周期リズム障害の治療方法
CA2474214A1 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
CA2502511A1 (en) * 2002-10-18 2004-05-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
JP4680903B2 (ja) 2003-07-29 2011-05-11 ハイ・ポイント・ファーマスーティカルズ、エルエルシー ピリダジニル−ピペラジンおよびそれらのヒスタミンｈ３受容体リガンドとしての使用
EP1670468A1 (en) * 2003-09-26 2006-06-21 Pfizer Products Inc. Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders
JP2007506731A (ja) * 2003-09-26 2007-03-22 ファイザー・プロダクツ・インク Ｎｐｙｙ５受容体アンタゴニストによる急速眼球運動（ｒｅｍ）睡眠妨害に関連する神経障害の治療
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
WO2005103039A1 (en) * 2004-04-15 2005-11-03 Neurocrine Biosciences, Inc. 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006036770A2 (en) * 2004-09-24 2006-04-06 Merck & Co., Inc. Combination therapy for the treatment of obesity
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007003604A2 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Hists1mine h3 receptor antagonists
EP1968596A4 (en) * 2005-12-22 2010-12-01 Icagen Inc ANTAGONISTS OF CALCIUM CHANNEL
EP2038256A1 (en) * 2006-05-23 2009-03-25 TransTech Pharma, Inc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
BRPI0711370A2 (pt) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina
WO2008033575A2 (en) * 2006-09-15 2008-03-20 Metabolon, Inc. Methods of identifying biochemical pathways
JP2010521450A (ja) * 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2280703A1 (en) * 2008-03-12 2011-02-09 Københavns Universitet (University Of Copenhagen) Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
US9120779B2 (en) 2008-12-03 2015-09-01 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2012081736A1 (en) 2010-12-17 2012-06-21 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
US10328064B2 (en) * 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
CN114728927A (zh) 2019-11-19 2022-07-08 莫达戈有限公司 用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的新颖化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853383A (en) 1975-03-03 1989-08-01 Merck & Co., Inc. β-blocking substituted imidazoles
US4440774A (en) 1975-03-03 1984-04-03 Merck & Co., Inc. 3-Amino-2-hydroxypropoxyaryl imidazole derivatives
JPH0251150A (ja) * 1988-08-12 1990-02-21 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0448765B1 (de) * 1990-03-30 1994-08-17 HEUMANN PHARMA GMBH & CO Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
BR9509610A (pt) 1994-11-07 1997-10-28 Pfizer Ligandos específicos de neuropeptideo Y1
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
BR9810651A (pt) * 1997-07-03 2000-10-03 Neurogen Corp Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos
AU757290B2 (en) * 1998-03-25 2003-02-13 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives

Also Published As

Publication number Publication date
PA8493701A1 (es) 2002-07-30
PE20010118A1 (es) 2001-02-03
TNSN00092A1 (fr) 2005-11-10
US20010039277A1 (en) 2001-11-08
US6355635B1 (en) 2002-03-12
AR028824A1 (es) 2003-05-28
HN2000000041A (es) 2001-02-02
GT200000057A (es) 2001-10-20
WO2000066578A1 (en) 2000-11-09
AU2935200A (en) 2000-11-17
US6514966B2 (en) 2003-02-04
MA26730A1 (fr) 2004-12-20
CO5170414A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
UY26130A1 (es) Compuestos para tratar la obesidad
GEP20074197B (en) 5ht2c receptor modulators
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
TW200612926A (en) Compounds and compositions as ppar modulators
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
TW200602330A (en) Compounds and compositions as PPAR modulators
EA200501868A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
TW200600505A (en) Compounds and compositions as ppar modulators
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
ATE432279T1 (de) Tricyclische delta-opioid-modulatoren
TNSN06381A1 (en) Compounds and compositions as ppar modulators

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100525